FimmCyte and Gedeon Richter Announce Strategic Partnership
FimmCyte AG, a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and option-to-license agreement with Gedeon Richter Plc., a leading...
Virometix AG Completes $15m Financing
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, completed a $15m financing round from existing shareholders. The funds will support continued clinical and development activities for V-212...
VISCHER advises Matignon Group on the acquisition of Praxis am Zeltweg
VISCHER advises Matignon Group on the acquisition of assets and agreements related to Praxis am Zeltweg, an established center in the field of medical aesthetics in the city of Zurich.
The VISCHER team includes Florian Fallegger...
Oncobit and ID Solutions Announce Strategic Partnership
Oncobit, a leading Swiss company in precision oncology, announces a strategic partnership with ID Solutions, a French company specializing in developing innovative diagnostic solutions in oncology. The goal of this collaboration...
VISCHER advises AFINUM on the acquisition of a majority stake in Ergon Informatik
VISCHER advises AFINUM on the acquisition of a majority stake in Ergon Informatik AG, a leading Swiss IT service provider with a focus on software development and digital security solutions.
The VISCHER team, led by Dr Jürg...
VISCHER advises AFINUM on the sale of Threema
AFINUM has entered into an agreement to sell Threema to Comitis Capital. Threema is a leading provider of highly secure digital communication solutions for enterprises and public institutions. The transaction is expected to close...
ASTRA Therapeutics Seed Round Closing
ASTRA Therapeutics SA, a start-up company developing precision drugs against eukaryotic pathogens, announced the successful closing of its CHF 7.75m seed financing round.
The investment was co-led by MIG Capital and Digitalis...
FoRx Therapeutics raises USD 50m in Series A Financing Round
FoRx Therapeutics AG, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, closed a USD 50m Series A Financing Round with existing investors including EQT Life Sciences, Pfizer Ventures, Novartis...
RELIEF and NeuroX complete Business Combination to form MindMaze
MindMaze Therapeutics Holding SA (SIX:MMTX; previously: RELIEF THERAPEUTICS Holding SA) acquired all the shares of NeuroX Group SA against issuance of new MMTX shares to complete their business combination by way of reverse...
Aukera Therapeutics gibt Financing bekannt
Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, recently announced that it has raised some CHF 4.5m to date and attracted new board member and investor David Urech. Other current investors...